NOTICE: This opinion is subject to
formal revision before publication in the United States Reports.
Readers are requested to notify the Reporter of Decisions, Supreme
Court of the United States, Washington, D. C. 20543,
pio@supremecourt.gov, of any typographical or other formal
errors.
SUPREME COURT OF THE UNITED STATES
_________________
Nos. 21–1326 and 22–111
_________________
UNITED STATES, et al.,
ex rel
. TRACY SCHUTTE
, et al
.,
PETITIONERS
21–1326
v.
SUPERVALU INC., et al.
UNITED STATES, et al.,
ex rel
. THOMAS PROCTOR, PETITIONER
22–111
v.
SAFEWAY, INC.
on writs of certiorari to the united states
court of appeals for the seventh circuit
[June 1, 2023]
Justice Thomas delivered the opinion of the
Court.
The False Claims Act (FCA) imposes liability on
anyone who “knowingly” submits a “false” claim to the Government.
31 U. S. C. §3729(a). In some cases, that rule is
straightforward: If a law authorized payment of $100 for “each”
medical test, and a doctor knows that he did five tests but submits
a claim for ten, then he has knowingly submitted a false claim. But
sometimes the rule is less clear. If a law authorized payment for
only “customary” medical tests, some doctors might be confused when
it came time for billing. And, while some doctors might honestly
mistake what that term means, others might correctly understand
whatever “customary” meant in this context—and submit claims that
were inaccurate anyway.
The cases before us today involve a legal
standard similar to that latter example: In certain circumstances,
pharmacies are required to bill Medicare and Medicaid for their
“usual and customary” drug prices. And, critically, these cases
involve defendants (respondents here) who may have correctly
understood the relevant standard and submitted inaccurate claims
anyway. The question presented is thus whether respondents could
have the scienter required by the FCA if they correctly understood
that standard and thought that their claims were inaccurate.
We hold that the answer is yes: What matters for
an FCA case is whether the defendant knew the claim was false.
Thus, if respondents correctly interpreted the relevant phrase and
believed their claims were false, then they could have known their
claims were false.
I
The FCA permits private parties to bring
lawsuits in the name of the United States—called
qui tam lawsuits—against those who they believe have
defrauded the Federal Government. §3730(b). Petitioners here
brought two such lawsuits against respondents, which are companies
that operate hundreds of retail drug pharmacies nationwide. In No.
21–1326, respondents are a group of companies that we collectively
call SuperValu; in No. 22–111, respondent is Safeway, Inc.
According to petitioners, respondents overcharged Medicare and
Medicaid programs for years when seeking reimbursement for
prescription drugs that the programs covered. In doing so,
petitioners argue, respondents defrauded the Government and
violated the FCA.
A
The claims at issue here relate to two federal
benefits programs: Medicaid, which establishes a cooperative
federal-state program that provides medical assistance to certain
low-income individuals, see 42 U. S. C. §1396
et seq., and Medicare, which provides federally funded
health insurance coverage to individuals who are 65 or older or who
are disabled, see 42 U. S. C. §1395
et seq.
As relevant here, States’ Medicaid plans may
offer outpatient prescription-drug coverage to qualifying
individuals. §1396d(a)(12). However, the Federal Centers for
Medicare and Medicaid Services (CMS) has promulgated regulations
that limit the amount these programs may reimburse for certain
drugs. See 42 CFR §447.512(b)(2) (2021). Those regulations limit
any reimbursement to the lower of two amounts, one of which is the
healthcare provider’s “usual and customary charges [for the drug]
to the general public.”
Ibid. State Medicaid agencies
likewise typically reimburse pharmacies for the lowest of different
amounts, one of which is often the pharmacy’s “usual and customary
charge” to the public. See CMS, Medicaid Covered Outpatient
Prescription Drug Reimbursement Information by State, Quarter
Ending September 2022 (Nov. 16, 2022),
https://www.medicaid.gov/medicaid/prescription-drugs/
state-prescription-drug-resources/medicaid-covered-
outpatient-prescription-drug-reimbursement-information-state/.
Through Medicare Part D, the Government also
offers prescription-drug coverage to beneficiaries. See 42
U. S. C. §1395w–101
et seq.; 42 CFR pt. 423.
To administer that coverage, CMS awards contracts to private plan
sponsors. See 42 U. S. C. §1395w–115; 42 CFR §§423.315,
423.329. Those plan sponsors, in turn, enter contracts with
pharmacies (sometimes through middlemen called pharmacy benefit
managers). Many of the contracts at issue here limited any
reimbursement to the pharmacy’s “usual and customary” price.
The bottom line is that, when respondents
submitted reimbursement claims to these entities, they often were
required to charge and disclose their “usual and customary” price
for that drug.[
1] But,
according to petitioners, respondents reported higher prices to
these entities than the ones that they usually and customarily
charged to the public.
B
According to petitioners, in 2006,
respondents’ competitor, Walmart, began offering 30-day supplies of
many drugs for $4.[
2] To
compete with Walmart, SuperValu and Safeway adopted price-match
programs in which their pharmacies would match a competitor’s lower
price at a customer’s request. SuperValu’s pharmacies would then
automatically apply that price to future refills of the drug for
those customers. Meanwhile, Safeway also adopted a “membership”
discount program through which customers received discounted
generic drug prices (often $4 for a 30-day supply). To enroll in
that membership program, customers had to fill out a form with only
basic information; petitioners argue that Safeway often already had
this information on file. SuperValu’s programs continued until
2016; Safeway’s continued until 2015.
Respondents’ discount programs turned out to be
popular. Though the exact extent of that popularity is disputed,
petitioners have presented evidence that the discounted prices
comprised a majority of sales for many drugs to customers who paid
in cash (and not through insurance) for at least some years during
the programs’ operation. For example, according to petitioners, a
majority of SuperValu’s 2012 cash sales for 44 of its 50
top-selling prescription drugs were made at those discounted
prices. And, according to petitioners, 88% of Safeway’s 2014 cash
sales for its top 20 generic drugs were at discounted rates.
Petitioners contend that those discounted prices
were actually respondents’ “usual and customary” prices—and that,
rather than submitting those lower prices for reimbursement,
respondents instead reported their higher, non-discounted prices.
For example, petitioners have presented evidence that Safeway
charged just $10 for 94% of its cash sales for a 90-day supply of a
cholesterol drug between 2008 and 2012. Yet Safeway apparently
reported prices as high as $108 as “usual and customary” during
that time. And petitioners presented evidence that, at least at
some times and for some drugs, SuperValu made more than 80% of its
cash sales for prices less than what it disclosed as its “usual and
customary” price.
To be sure, the phrase “usual and customary” on
its face appears somewhat open to interpretation. But petitioners
contend that respondents were informed that their lower, discounted
prices were their “usual and customary” prices, believed their
discounted prices were their “usual and customary” prices, and
tried to hide their discounted prices from regulators and
contractors. Petitioners have presented evidence that they claim
supports that theory. For example, both SuperValu and Safeway
received a notice in 2006 from a pharmacy benefit manager stating
that the phrase “usual and customary” refers to discounted prices;
Safeway apparently received the same message from state Medicaid
agencies. And executives at both companies raised concerns about
letting state agencies or pharmacy benefit managers find out about
their discounted prices.
For example, some emails between SuperValu
executives described their discount program as a “stealthy
approach” and noted concern for the “integrity” of their “U&C
price” claims. App. to Pet. for Cert. in No. 21–1326, p. 67a
(internal quotation marks omitted). An executive at Safeway
similarly stated that “[w]e may have some issues with U&C” and
that “if you [match a] price offer, that becomes your usual and
customary [price] for that day.” 30 F. 4th 649, 667 (CA7 2022)
(internal quotation marks omitted). Other documents directed
Safeway’s employees to match Walmart prices, but cautioned that
employees should not “
put any of this in writing to stores
because our official policy is we do not match.”
Id., at
666. Petitioners argue that this and other evidence show that
respondents thought that their claims were inaccurate yet submitted
them anyway.
C
Before proceeding, some context about how
these cases reached us is useful to understand the question
presented. The FCA (as relevant here) imposes liability on those
who “knowingly presen[t] . . . a false or fraudulent
claim for payment or approval.” §3729(a)(1)(A). Thus, two essential
elements of an FCA violation are (1) the falsity of the claim and
(2) the defendant’s knowledge of the claim’s falsity.
In SuperValu’s case, the District Court ruled
against SuperValu on the falsity element—it determined that
SuperValu’s discounted prices were its “usual and customary” prices
and that, by not reporting them, SuperValu submitted claims that
were false. But, the District Court then granted summary judgment
for SuperValu based on the scienter element, holding SuperValu
could not have acted “knowingly.” Soon after, it granted Safeway
summary judgment on the same basis.
The Seventh Circuit affirmed. 9 F. 4th 455
(2021). In doing so, it relied heavily on
Safeco Ins. Co. of
America v.
Burr,
551 U.S.
47 (2007)—a case that interpreted the term
“ ‘willfully’ ” in the Fair Credit Reporting Act (FCRA),
id., at 52. Specifically, the Seventh Circuit read
Safeco to dictate a two-step inquiry for ascertaining
whether a defendant acted recklessly or knowingly. At step one, the
Seventh Circuit took
Safeco to ask whether a defendant’s
acts were consistent with any objectively reasonable interpretation
of the relevant law that had not been ruled out by definitive legal
authority or guidance. This step, the Seventh Circuit held, applied
regardless of whether the defendant actually believed such an
interpretation at the time of its claims. Only if the defendant’s
acts were not consistent with any objectively reasonable
interpretation would the court proceed, at step two, to consider
the defendant’s actual subjective thoughts. Thus, under the Seventh
Circuit’s approach, a claim would have to be objectively
unreasonable, as a legal matter, before a defendant could be held
liable for “knowingly” submitting a false claim, no matter what the
defendant thought.
Turning to the facts here, the Seventh Circuit
held that respondents were entitled to summary judgment because
their actions were consistent with an objectively reasonable
interpretation of the phrase “usual and customary.” Specifically,
the court reasoned that the phrase
could have been
understood as referring to respondents’ retail prices, not their
discounted prices—even if the phrase, correctly understood,
referred to their discounted prices. It thus did not matter whether
respondents thought that their discounted prices were actually
their “usual and customary” prices. What mattered, instead, was
that someone else, standing in respondents’ shoes, may have
reasonably thought that the retail prices were what counted.
We granted certiorari, see 598 U. S. ___
(2023), to resolve that legal question: If respondents’ claims were
false and they actually thought that their claims were
false—because they believed that their reported prices were not
actually their “usual and customary” prices—then would they have
“knowingly” submitted a false claim within the FCA’s meaning? Or is
the Seventh Circuit correct—that respondents could not have
“knowingly” submitted a false claim unless no hypothetical,
reasonable person could have thought that their reported prices
were their “usual and customary” prices?
It is equally important to recognize what we did
not grant certiorari to review: We are not reviewing the
meaning of the phrase “usual and customary” or whether any of
respondents’ claims were, in fact, inaccurate or otherwise false.
Nor are we reviewing whether respondents actually thought that the
phrase “usual and customary” referred to their discounted prices.
Nor, for that matter, are we reviewing any factual disputes about
what respondents did or did not believe or do. These cases come to
us from the grant of summary judgment to respondents on one
discrete legal issue, and we granted certiorari to resolve only
that issue.
II
Based on the FCA’s statutory text and its
common-law roots, the answer to the question presented is
straightforward: The FCA’s scienter element refers to respondents’
knowledge and subjective beliefs—not to what an objectively
reasonable person may have known or believed. And, even though the
phrase “usual and customary” may be ambiguous on its face, such
facial ambiguity alone is not sufficient to preclude a finding that
respondents knew their claims were false.
A
We start, as always, with the text of the FCA.
See
Universal Health Services, Inc. v.
United States
ex rel. Escobar, 579 U.S. 176, 187 (2016). Here, the FCA
defines the term “knowingly” as encompassing three mental states:
First, that the person “has actual knowledge of the information,”
§3729(b)(1)(A)(i). Second, that the person “acts in deliberate
ignorance of the truth or falsity of the information,”
§3729(b)(1)(A)(ii). And, third, that the person “acts in reckless
disregard of the truth or falsity of the information,”
§3729(b)(1)(A)(iii). In short, either actual knowledge, deliberate
ignorance, or recklessness will suffice.[
3]
That three-part test largely tracks the
traditional common-law scienter requirement for claims of fraud.
See Restatement (Second) of Torts §526 (1976); Restatement (Third)
of Torts: Liability for Economic Harm §10 (2018). For example, one
widely cited English decision,
Derry v.
Peek, [1889]
14 App. Cas., articulated the rule as follows: “[F]raud is proved
when it is shewn that a false representation has been made (1)
knowingly, or (2) without belief in its truth, or (3) recklessly,
careless whether it be true or false.”
Id., at 374 (judgment
of Lord Herschell). And, capturing the FCA’s use of the term
“deliberate ignorance,” that decision noted that an action for
fraud would lie if “a person making a false statement had shut his
eyes to the facts, or purposely abstained from inquiring into
them.”
Id., at 376. Those standards have been cited and
widely adopted by American courts in the century since. See 3 D.
Dobbs, P. Hayden, & E. Bublick, Law of Torts §665, p. 645
(2d ed. 2011) (Dobbs); Restatement (Second) of Torts, App. §526,
Reporter’s Note.
That the text of the FCA tracks the common law
is unsurprising because, as we have recognized, the FCA is largely
a fraud statute. See
Escobar, 579 U. S., at 187–188,
and n. 2. Indeed, the FCA was first enacted in 1863 to
“ ‘sto[p] the massive frauds perpetrated by large contractors
during the Civil War.’ ”
Id., at 181. To this day, the
FCA refers to “ ‘false or
fraudulent’ ” claims,
pointing directly to “the common-law meaning of fraud.”
Id.,
at 187 (emphasis added). In the absence of statutory text to the
contrary, we would assume that “ ‘Congress intends to
incorporate the well-settled meaning’ ” of such a common-law
term. See
ibid. And here, the FCA’s definition of
“knowingly” confirms that assumption by largely tracking the
common-law scienter standards for fraud.
On their face and at common law, the FCA’s
standards focus primarily on what respondents thought and believed.
First, the term “actual knowledge” refers to whether a person is
“aware of ” information.[
4] See
Intel Corp. Investment Policy Comm. v.
Sulyma, 589 U. S. ___, ___–___ (2020) (slip op., at
6–7);
Escobar, 579 U. S., at 191 (“A defendant can have
‛actual knowledge’ that a condition is material without the
Government expressly calling it a condition of payment”); Black’s
Law Dictionary 784 (5th ed. 1979) (“to understand,” or “the
perception of the truth”); Restatement (Second) of Torts §526, and
Comment
c. Second, the term “deliberate ignorance”
encompasses defendants who are aware of a substantial risk that
their statements are false, but intentionally avoid taking steps to
confirm the statement’s truth or falsity. See
Global-Tech
Appliances, Inc. v.
SEB S. A.,
563 U.S.
754, 769 (2011); Black’s Law Dictionary, at 672 (“[v]oluntary
ignorance”);
Derry, 14 App. Cas., at 376. And, third, the
term “reckless disregard” similarly captures defendants who are
conscious of a substantial and unjustifiable risk that their claims
are false, but submit the claims anyway. See Black’s Law
Dictionary, at 1142;
Farmer v.
Brennan,
511 U.S.
825, 836 (1994); Restatement (Third) of Torts §10, Comment
c.[
5]
Again, that tracks traditional common-law fraud,
which ordinarily “depends on a subjective test” and the defendant’s
“culpable state of mind.”
Id., §10, Comment
a. What
typically matters at common law is whether the defendant made the
false statement “without belief in its truth or recklessly,
careless of whether it is true or false.” Restatement (Second) of
Torts §526, Comment
e. If a defendant knows that he “lack[s
an] honest belief ” in the statement’s truth, that is often
enough to establish scienter for fraud.
Id., Comment
d.; Dobbs §665, at 647.
Both the text and the common law also point to
what the defendant thought when submitting the false claim—not what
the defendant may have thought
after submitting it. As noted
above, the text encompasses those who “knowingly presen[t]
. . . a false or fraudulent claim”; the term “knowingly”
thus modifies present-tense verbs like “presents.” §3729(a)(1)(A).
As such, the focus is not, as respondents would have it, on
post
hoc interpretations that might have rendered their claims
accurate. It is instead on what the defendant knew when presenting
the claim. See also Restatement (Second) of Torts §526, Comment
e (“It is enough that being conscious that he has neither
knowledge nor belief in the existence of the matter he chooses to
assert it as a fact”); accord,
Halo Electronics, Inc. v.
Pulse Electronics, Inc., 579 U.S. 93, 105 (2016)
(“[C]ulpability is generally measured against the knowledge of the
actor at the time of the challenged conduct”).
B
The difficulty here, however, is that the
phrase “usual and customary” is, on its face, less than perfectly
clear. We assume (as the District Court ruled in SuperValu’s case)
that respondents’ “usual and customary” prices were their
discounted ones; if so, it might have been a forgivable mistake if
respondents had honestly read the phrase as referring to retail
prices, not discounted prices. But the Seventh Circuit did not hold
that respondents made an honest mistake; it held that, because
other people might make an honest mistake, defendants’
subjective beliefs became irrelevant to their scienter. Respondents
make three main arguments in support of that rule. But none is
persuasive.
1
Respondents first focus on the inherent
ambiguity of the phrase at issue here, asserting that they could
not have “known” that their claims were inaccurate because they
could not have “known” what the phrase “usual and customary”
actually meant. The most that is possible, respondents posit, is
that they took a (correct) guess.
We disagree. Although the terms, in isolation,
may have been somewhat ambiguous, that ambiguity does not preclude
respondents from having learned their correct meaning—or, at least,
becoming aware of a substantial likelihood of the terms’ correct
meaning. To illustrate why, consider a hypothetical driver who sees
a road sign that says “Drive Only Reasonable Speeds.” That driver,
without any more information, might have no way of knowing what
speeds are reasonable and what speeds are too fast. But then assume
that the same driver was informed earlier in the day by a police
officer that speeds over 50 mph are unreasonable and then noticed
that all the other cars around him are going only 48 mph. In that
case, the driver might know that “Reasonable Speeds” are anything
under 50 mph; or, at the least, he might be aware of an
unjustifiably high risk that anything over 50 mph is unreasonable.
Indeed, if the same police officer later pulled the driver over, we
imagine that he would be hard pressed to argue that some other
person might have understood the sign to allow driving at 80
mph.
The same analysis applies here. According to
petitioners, respondents received notice that the phrase “usual and
customary” referred to their discounted prices (in some cases, it
seems, from the same entities to which they reported their prices).
And, according to petitioners, respondents comprehended those
notices and then tried to hide their discounted prices. If that is
true, then perhaps respondents actually knew what the phrase meant;
or perhaps respondents were aware of an unjustifiably high risk
that the phrase referred to their discounted prices. And, if that
is true, then respondents may have known that their claims were
false. The facial ambiguity of the phrase thus does not by itself
preclude a finding of scienter under the FCA.
2
Second, like the Seventh Circuit, respondents
rely on
Safeco. They contend that
Safeco already
interpreted the common-law definitions of “knowing” and “reckless”
and that it did so by looking first at whether the defendant’s
“reading of the statute” was “objectively unreasonable.” 551
U. S., at 69. Accordingly, respondents conclude that, because
the FCA has the same common-law terms, it should be read with the
same, objective common-law focus.
This argument fails twice over. First,
Safeco interpreted a different statute, the FCRA, which had
a different
mens rea standard, “ ‘willfully.’ ”
Id., at 52 (quoting 15 U. S. C. §1681n(a)). While
Safeco did reference the common law’s standards for
“knowing” and “reckless” conduct, see 551 U. S., at 59–60,
68–69, its interpretation was ultimately tied to the FCRA’s
particular text. To take
Safeco as establishing categorical
rules for those terms would accordingly “abandon the care we have
traditionally taken to construe such words in their particular
statutory context.”
Jerman v.
Carlisle, McNellie, Rini,
Kramer & Ulrich, L. P. A.,
559 U.S.
573, 585 (2010). And, as explained above, the FCA’s scienter
standards are plainly satisfied by a defendant’s conscious belief
that his claims are false.
Second,
Safeco did not purport to set
forth the purely objective safe harbor that respondents invoke. To
the contrary,
Safeco stated that a person is reckless if he
acts “
knowing or having reason to know of facts which would
lead a reasonable man to realize” that his actions were
substantially risky. 551 U. S., at 69 (emphasis added;
internal quotation marks omitted). Or, as
Safeco
alternatively put it, the common law of recklessness
contained an objective standard because it encompassed
actions involving “an unjustifiably high risk of harm that is
either known
or so obvious that it should be known.”
Id., at 68 (emphasis added; internal quotation marks
omitted); see also Restatement (Second) of Torts §500, Comment
a (1964) (“Recklessness may consist of either of two
different types of conduct. In one the actor knows . . .
of facts which create a high degree of risk”). Thus, as we have
stated previously, “[n]othing in
Safeco suggests that we
should look to facts that the defendant neither knew nor had reason
to know at the time he acted.”
Halo Electronics, 579
U. S., at 106.[
6] By a
similar token here, we do not look to legal interpretations that
respondents did not believe or have reason to believe at the time
they submitted their claims.
3
Respondents make one more argument,
approaching the issue from a somewhat different angle. They contend
that, at common law, their claims would not be actionable as
fraudulent even if their reported prices were not accurate under
the correct meaning of “usual and customary.” Their argument is as
follows: At common law, misrepresentations of law are not
actionable; only misrepresentations of fact are. Because the FCA
incorporates the common law of fraud, it embodies that same
limitation. And the claims here would have been knowingly false
only because respondents correctly understood what “usual and
customary” meant. Therefore, respondents conclude, their reports
were not false because of any misrepresentation of fact; to the
contrary, their claims would have been false only because of their
view of the law.
But those premises do not support that
conclusion. To be sure, many courts appear to have stated—as a
general rule—that misrepresentations of law are not actionable at
common law. See Restatement (Second) of Torts §545; W. Keeton, D.
Dobbs, R. Keeton, & D. Owen, Prosser and Keeton on Law of Torts
§109, pp. 758–759 (5th ed. 1984) (Prosser & Keeton). So,
for example, if a defendant had told the plaintiff, “your claim
will be dismissed because federal courts lack jurisdiction over
claims like that,” that representation might not be actionable as a
fraud. See
ibid.;
Utah Power & Light Co. v.
Federal Ins. Co., 983 F.2d 1549, 1556 (CA10 1993). Varying
rationales appear to have been given for this rule, including that
such statements are of mere opinion and that no one could
justifiably rely on them. See Dobbs §677, at 688.
For purposes of these cases, we assume without
deciding that the FCA incorporates some version of this rule; even
then, the rule has significant limits on its own terms. As relevant
here, statements involving some legal analysis remain actionable if
they “carry with [them] by implication” an assertion about “facts
that justify” the speaker’s statement. Restatement (Second) of
Torts §545, Comment
c; see also Prosser & Keeton §109,
at 759. So, as a contrasting example, a person might be liable for
falsely stating that “the plumbing work that I did on your house
complied with state law.” See
Sorenson v.
Gardner,
215 Ore. 255, 261, 334 P.2d 471, 474 (1959). That is because such a
statement says something about both the correct meaning of building
codes
and the facts about the home’s construction.
Ibid.; see also
Hoyt Properties, Inc. v.
Production Resource Group, L. L. C., 736 N.W.2d
313, 319 (Minn. 2007). And homeowners might justifiably rely on
that latter representation about the facts, which thus could be
actionable as fraud.
Respondents’ disclosures here sound more like
our hypothetical plumber, not our hypothetical legal advisor.
Rather than saying, “this is what ‛usual and customary’ means,”
respondents essentially said, “this is what
our ‛usual and
customary’ prices are.” In doing so, they plainly implied facts
about their prices that were not known to the plan sponsors,
pharmacy benefit managers, and state Medicaid agencies that
received their claims. Petitioners’ cases thus make out a valid
fraud theory even under respondents’ common-law rule.
* * *
Under the FCA, petitioners may establish
scienter by showing that respondents (1) actually knew that their
reported prices were not their “usual and customary” prices when
they reported those prices, (2) were aware of a substantial risk
that their higher, retail prices were not their “usual and
customary” prices and intentionally avoided learning whether their
reports were accurate, or (3) were aware of such a substantial and
unjustifiable risk but submitted the claims anyway. §3729(b)(1)(A).
If petitioners can make that showing, then it does not matter
whether some other, objectively reasonable interpretation of “usual
and customary” would point to respondents’ higher prices. For
scienter, it is enough if respondents believed that their claims
were not accurate.
We need not address any of the other factual or
legal disputes involved in these cases, including whether
petitioners have made a showing sufficient under the correct legal
standard to preclude summary judgment. Nor do we need to address
any of the parties’ policy arguments, which “cannot supersede the
clear statutory text.”
Escobar, 579 U. S., at 192. We
accordingly vacate the judgments below and remand these cases to
the Seventh Circuit for further proceedings consistent with this
opinion.
It is so ordered.
Comments
Be the first to comment
Leave a Comment